Stable liposomal vitamin D formulations for enhanced stability and availability
Molecular Express, Inc. presents an advanced liposomal formulation of Vitamin D designed to enhance its stability and availability. Utilizing 20 years of expertise in liposomal technology, this formulation addresses the hydrophobic nature of Vitamin D, making it ideal for various applications.
Overview
Molecular Express, Inc. introduces a novel liposomal formulation of Vitamin D aimed at significantly improving its stability and bioavailability. Vitamin D's hydrophobic nature often poses challenges in maintaining its stability. By encapsulating Vitamin D in liposomes, we enhance its stability and absorption, making it more effective for dietary and pharmaceutical applications. This innovation leverages over two decades of expertise in liposomal and formulation technologies, offering a tailored solution to meet specific formulation needs.
Technical specifications
Key features:
- Liposomal encapsulation of hydrophobic Vitamin D to increase stability
- Tailored formulation development based on extensive experience and expertise
- Comprehensive testing phases including formulation, quantification, and in vitro assessments
- In vitro tests potentially include stability under simulated digestion and absorption efficacy using Caco-2 cells
Technology readiness level
This liposomal Vitamin D formulation has reached Technology Readiness Level 9, indicating that it is fully developed and ready for commercial deployment following extensive validation.
About Molecular Express, Inc.
Molecular Express, Inc. is a biotechnology company that specializes in advanced formulation services to accelerate the development of vaccines, therapeutics, and small molecule drugs. The company utilizes its proprietary Molecular GPS™ and VesiVax® platforms for targeted drug delivery, nanoparticle design, and engineering. By leveraging these advanced delivery systems, the company provides essential support for protein processing, production, and rigorous analytical testing. Its expertise enables researchers to conjugate target molecules and stabilize compounds, ensuring they meet the required quality standards for preclinical and clinical development. Molecular Express, Inc. operates as a key research and development subsidiary of Molecular GPS Technologies™, collaborating with academic institutions and government agencies to bring innovative scientific research to market.
The company plays a vital role in life sciences by helping partners secure funding and grants to translate groundbreaking discoveries into viable clinical solutions. By providing efficient, scalable protein production and customized formulation services, it addresses significant bottlenecks in therapeutic development, such as supply constraints and manufacturing complexity. Through its work with the NIH and other organizations, Molecular Express contributes to public health by developing specialized treatments, including synthetic lung surfactants and immunomodulatory adjuvants. This collaborative, research-driven approach allows the company to support a wide range of projects, from oncology and infectious disease vaccines to novel medical imaging agents and addiction therapies, ultimately bridging the gap between bench-top research and real-world medical applications.
delivered to your inbox.